HAIFA, Israel and MIAMI, Florida – INSIGHTEC®, a commercial-stage medical technology company revolutionizing surgery with incisionless MRI-guided focused ultrasound (MRgFUS) announced today the closing of a $150 million Series E private equity investment round. Koch Disruptive Technologies (KDT), a subsidiary of Koch Industries, focused on finding and funding innovative and emerging companies, led the round with a $100 million investment.
More than nine in 10 nurse managers see voice recognition and telehealth technologies intensifying over the next five years, while secure text messaging, voice communication and photographing wounds and skin conditions will be nearly universal. Major growth is expected in areas like remote patient monitoring.
Wearables, like smartwatches and fitness trackers, are popular with business professionals, and for good reason. The devices can collect data and provide insights, allowing wearers to track their fitness and productivity to reach their goals faster.
The interest in Blockchain and distributed ledger technology (DLT) has exploded in recent years with a large focus on the financial industry. Meanwhile, medical and pharmaceutical companies around the world are looking to DLT as a means of solving, securing, and streamlining their businesses. While there are many applications for DLT within the medical industry, one area where the technology excels is within supply chains.
This year could see a transformation in the Japanese pharma market, according to a new report, with strong growth stemming from increased use of generics, biosimilars and stronger links with the global industry.
The year’s merger-and-acquisition trend continues. Today, the last day of January, Bothell, Washington-based Seattle Genetics announced it is buying Seattle-based Cascadian Therapeutics for about $614 million.
BridgeBio Pharma today announced that it is has licensed infigratinib (BGJ398), a highly potent and selective inhibitor of the tyrosine kinase receptor FGFR, from Novartis. In addition, BridgeBio announced that it was launching new subsidiary QED Therapeutics to drive development of infigratinib with an initial financial commitment of $65 million.
your submission has already been received.
Please enter a valid Email address！
The most relevant industry news & insight will be sent to you every two weeks.